Short Answer
The decision is determined not by whether your team is capable, but by three axes: independence, continuity, and signature. A medical-AI device's pivotal (key) clinical-validation study is stronger in the eyes of the regulator and the reviewer when it is designed and conducted by a party that is methodologically independent from the team that developed the model, because when the same hand that optimizes the model is also the one that judges it, the conflict of interest becomes visible in the file. The in-house approach is right for continuous model iteration, a large data-science team, and post-market surveillance (PMS). An external independent methodologist, on the other hand, is right for the episodic but high-stakes need: when a standalone performance study with a pre-locked protocol, the core of the TITCK/EU-MDR/FDA file, and a named methodologist's signature are required. In practice, the most common solution is hybrid: the in-house team develops and monitors, while the external methodologist designs the pivotal study, runs its statistics, and signs it.
Serteser Consulting is run by a biomedical engineer (BME MSc) who has developed a medical-AI medical device and published it in a peer-reviewed international journal. As a methodologist independent from your development team, we design the pivotal validation study for your SaMD/AI devices, run its standalone analysis, and deliver it with a named signature in the regulatory file.
As a medical-AI team grows, an inevitable question arrives: should we build clinical validation in-house, or bring in an independent external methodologist? This is often asked as "should we hire a full-time biostatistician," but that is not the right question. The right question is which work is continuous and which is episodic, and where the regulatory file expects an independent signature.
This article offers a framework for making the decision not on an emotional axis ("we do our own work ourselves") or a cost axis ("consultants are expensive"), but on the defensibility of your file.
Validation Is Not a Continuation of Development
The most critical principle in the decision is this: validation is not the next step of model development, but an activity methodologically separate from it. The team that trains the model naturally optimizes to raise the target metric; threshold selection, data splitting, and hyperparameter decisions serve this purpose. That same team then being the sole judge of the question "is this model good" is the first structural weakness the regulator and the reviewer notice.
Independent validation is therefore set up adversarially: model weights, preprocessing, and the decision threshold are locked before the validation data is seen; those who set the reference standard do not see the model output; the analysis plan is written before the data. There are companies that build this independence entirely in-house, but building it requires a methodology function within the team that is separate from development and reports separately. In most early-stage teams, this separation does not exist.
When Is In-House the Right Decision?
In-house validation capacity is the economical and correct choice when the following conditions are met together:
- Continuous iteration: If the model is updated frequently and every version requires re-evaluation, outsourcing this work each time is both slow and expensive.
- Internal depth: If the team already has a function that reports independently from development and has depth in biostatistics and clinical-study design.
- Post-market surveillance (PMS): Performance drift tracking, continuous monitoring on real-world data, and the complaint-CAPA loop are continuous by nature and should live in-house.
- Data and pipeline ownership: If reproducibility, version control, and data management have matured in-house.
In short: ownership of the pipeline and continuous monitoring should stay in-house. This is the part that cannot be outsourced.
When Is an External Independent Methodologist the Right Decision?
An external independent methodologist is the right choice when the need is episodic but the stakes are high:
- Pivotal (key) study: The standalone performance study at the core of the CE/TITCK/FDA file is needed once or a few times a year; carrying the salary of a full-time PhD biostatistician for this is disproportionate for most teams.
- Independence requirement: The regulator and the notified body count a judgment separate from the development team as stronger evidence. An external methodologist provides this independence structurally.
- Named signature: The EU-MDR clinical evaluation file (the MEDDEV 2.7/1 Rev 4 structure, the MDCG 2020-1 three-component model) and peer-reviewed publication expect a named methodologist who conducts the analysis and stands behind it. An anonymous internal table and a signed methodology section do not carry the same weight.
- Methodological credibility: A pre-locked analysis plan, external validation design, and compliance with reporting standards (TRIPOD-AI, STARD-AI) go faster with someone who has done this work again and again.
Hybrid Model: The Most Common Solution
In practice, the winning structure is usually not binary but hybrid. The in-house team develops the model, owns the pipeline, and runs post-market surveillance. The external independent methodologist, meanwhile, designs the pivotal validation study, locks the protocol before the data, runs the standalone analysis, writes the statistics and clinical-evaluation sections of the file, and signs as the named methodologist.
This structure meets two needs at once: the pipeline and continuous monitoring stay in-house (speed and ownership), while the key evidence comes from an independent hand (defensibility). It also scales the cost of a full-time senior biostatistician to the moments it is actually needed.
To clarify which structure is right for you to run your device's pivotal validation study, you can request a 15-minute free scoping.
Decision Matrix: Ask Yourself
| Question | In favor of in-house | In favor of external methodologist |
|---|---|---|
| Is the need continuous or episodic? | Continuous (every version is re-evaluated) | Episodic (one or two pivotal studies a year) |
| Is there a methodology function independent from development? | Yes | No, or high conflict-of-interest risk |
| Does the file expect a named, defensible signature? | No (internal use) | Yes (regulator/reviewer/notified body) |
| Is the cost of a full-time senior biostatistician proportionate? | Yes (there is scale) | No (expensive for an episodic need) |
For most early-stage medical-AI companies, the right column of the matrix outweighs: the need is episodic, independence is critical in the file, and a full-time hire is disproportionate. In contrast, the pipeline and monitoring should always stay in-house.
Conclusion: The Question Is Not Capability, but Independence and Continuity
The decision is not the question "can we do it"; most good teams can technically do it. The decision is the question of which work is continuous (in-house) and which work is episodic-but-requires-an-independent-signature (external). A pivotal validation that is independent from your development team, pre-locked, and signed by a named methodologist is the most heavily scrutinized but least negotiable part of your regulatory and reviewer file. Building it with the right structure cannot be reproduced after the fact.